IN2012DN03130A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN03130A IN2012DN03130A IN3130DEN2012A IN2012DN03130A IN 2012DN03130 A IN2012DN03130 A IN 2012DN03130A IN 3130DEN2012 A IN3130DEN2012 A IN 3130DEN2012A IN 2012DN03130 A IN2012DN03130 A IN 2012DN03130A
- Authority
- IN
- India
- Prior art keywords
- propofol
- compositions
- aerosols
- buccal
- capsules
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C19/00—Acyclic saturated compounds containing halogen atoms
- C07C19/08—Acyclic saturated compounds containing halogen atoms containing fluorine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09014548A EP2332525A1 (en) | 2009-11-23 | 2009-11-23 | Pharmaceutical composition comprising propofol |
| PCT/EP2010/067938 WO2011061332A1 (en) | 2009-11-23 | 2010-11-22 | Pharmaceutical composition comprising propofol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN03130A true IN2012DN03130A (enExample) | 2015-09-18 |
Family
ID=41694756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3130DEN2012 IN2012DN03130A (enExample) | 2009-11-23 | 2010-11-22 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8796340B2 (enExample) |
| EP (2) | EP2332525A1 (enExample) |
| JP (1) | JP5707009B2 (enExample) |
| KR (1) | KR20120104262A (enExample) |
| CN (1) | CN102753159B (enExample) |
| AU (1) | AU2010320823B2 (enExample) |
| BR (1) | BR112012012108A2 (enExample) |
| CA (1) | CA2776855C (enExample) |
| ES (1) | ES2450423T3 (enExample) |
| IN (1) | IN2012DN03130A (enExample) |
| MX (1) | MX2012005881A (enExample) |
| WO (1) | WO2011061332A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2564502T3 (es) | 2010-03-17 | 2016-03-23 | Novaliq Gmbh | Composición farmacéutica para el tratamiento de la presión intraocular aumentada |
| EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
| EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
| CN103561724B (zh) | 2011-05-25 | 2016-06-29 | 诺瓦利克有限责任公司 | 给药给甲的药物组合物 |
| JP6039145B2 (ja) | 2011-05-25 | 2016-12-07 | ノバリック ゲーエムベーハー | 半フッ化アルカンを基礎にした局所薬学的組成物 |
| GB201116271D0 (en) | 2011-09-21 | 2011-11-02 | Univ Cardiff | Dispersion anaesthetic device |
| PT2806886T (pt) | 2012-01-23 | 2017-03-24 | Novaliq Gmbh | Composições de proteínas estabilizadas baseadas em alcanos semifluorados |
| EP2895144B1 (en) | 2012-09-12 | 2017-01-11 | Novaliq GmbH | Semifluorinated alkane compositions |
| MX363182B (es) | 2012-09-12 | 2019-03-13 | Novaliq Gmbh | Composiciones que comprenden mezclas de alcanos semifluorados. |
| PL2708228T3 (pl) * | 2012-09-12 | 2018-11-30 | Novaliq Gmbh | Kompozycje do przemywania oczu |
| DK3024484T3 (en) | 2013-07-23 | 2018-10-08 | Novaliq Gmbh | STABILIZED ANTIBODY COMPOSITIONS |
| EP2944324A1 (de) * | 2014-05-13 | 2015-11-18 | LTS LOHMANN Therapie-Systeme AG | Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen |
| EP3206683A4 (en) | 2014-10-16 | 2018-06-13 | The Board of Trustees of the Leland Stanford Junior University | Novel methods, compounds, and compositions for anesthesia |
| EP3722274B1 (en) | 2015-09-30 | 2023-06-07 | Novaliq GmbH | 2-perfluorobutyl pentane for ophthalmic administration |
| US20170087100A1 (en) | 2015-09-30 | 2017-03-30 | Novaliq Gmbh | Semifluorinated compounds and their compositions |
| DK3442480T3 (da) | 2016-06-23 | 2020-01-13 | Novaliq Gmbh | Fremgangsmåde til topisk indgivelse |
| KR102614858B1 (ko) | 2016-09-22 | 2023-12-18 | 노바리크 게엠베하 | 안검염 치료에 사용되는 약제학적 조성물 |
| AU2017329983B2 (en) | 2016-09-23 | 2022-05-05 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
| MX381639B (es) | 2016-12-23 | 2025-03-13 | Novaliq Gmbh | Composicion oftalmica para el tratamiento de la enfermedad del ojo seco. |
| PL3612228T3 (pl) | 2017-04-21 | 2024-04-08 | Dermaliq Therapeutics, Inc. | Kompozycje jodu |
| US11278503B2 (en) | 2017-05-12 | 2022-03-22 | Novaliq Gmbh | Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions |
| JP7814839B2 (ja) | 2017-09-27 | 2026-02-17 | ノバリック ゲーエムベーハー | 眼疾患の治療に使用するためのラタノプロストを含む眼科用組成物 |
| CN111182893A (zh) | 2017-10-04 | 2020-05-19 | 诺瓦利克有限责任公司 | 包含f6h8的眼用组合物 |
| US11576893B2 (en) | 2018-03-02 | 2023-02-14 | Novaliq Gmbh | Pharmaceutical compositions comprising nebivolol |
| AU2019246035B2 (en) | 2018-03-28 | 2024-07-18 | Novaliq Gmbh | Pharmaceutical composition comprising timolol |
| JP7855312B2 (ja) | 2018-04-27 | 2026-05-08 | ノバリック ゲーエムベーハー | 緑内障の治療のためのタフルプロストを含む眼科用組成物 |
| WO2020064549A1 (en) | 2018-09-27 | 2020-04-02 | Novaliq Gmbh | Lipid barrier repair |
| CA3112031A1 (en) | 2018-10-12 | 2020-04-16 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
| EP3923907B1 (en) | 2019-02-13 | 2024-09-25 | Novaliq GmbH | Compositions and methods for the treatment of ocular neovascularization |
| CN114449999A (zh) | 2019-09-06 | 2022-05-06 | 诺瓦利克有限责任公司 | 用于治疗葡萄膜炎的眼用组合物 |
| EP3912622A1 (en) | 2020-05-19 | 2021-11-24 | tesa Labtec GmbH | Oral film for safe administration of api |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5496537A (en) * | 1995-03-23 | 1996-03-05 | Henry; Richard A. | Propofol hydrofluorocarbon propellant formulations |
| DE19536504C2 (de) | 1995-09-29 | 1999-09-23 | H Meinert | Verwendung fluorierter Alkane |
| WO2000054588A1 (en) * | 1999-03-15 | 2000-09-21 | John Claude Krusz | Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages |
| GB0124071D0 (en) * | 2001-10-08 | 2001-11-28 | Kbig Ltd | Improvement in the administration of high boiling point aneasthetics |
| WO2005067517A2 (en) * | 2004-01-02 | 2005-07-28 | Wisconsin Alumni Research Foundation | Encapsulation of chemical compounds in fluorous-core and fluorous-inner-shell micelles formed from semifluorinated-block or fluorinated-block copolymers |
| DE102004030044A1 (de) | 2004-06-22 | 2006-01-12 | Birken Gmbh | Triterpenhaltiger Oleogelbildner, triterpenhaltiges Oleogel und Verfahren zur Herstellung eines triterpenhaltigen Oleogels |
| US9000048B2 (en) * | 2006-11-28 | 2015-04-07 | Wisconsin Alumni Research Foundation | Fluoropolymer-based emulsions for the intravenous delivery of fluorinated volatile anesthetics |
| PL2110126T3 (pl) * | 2008-04-18 | 2012-04-30 | Novaliq Gmbh | Zastosowanie do inhalacji i zakraplania semifluorowanych alkanów jako nośników substancji aktywnych w strefie wewnątrzpłucnej |
-
2009
- 2009-11-23 EP EP09014548A patent/EP2332525A1/en not_active Withdrawn
-
2010
- 2010-11-22 US US13/511,184 patent/US8796340B2/en active Active
- 2010-11-22 AU AU2010320823A patent/AU2010320823B2/en active Active
- 2010-11-22 CA CA2776855A patent/CA2776855C/en active Active
- 2010-11-22 KR KR1020127016348A patent/KR20120104262A/ko not_active Withdrawn
- 2010-11-22 MX MX2012005881A patent/MX2012005881A/es not_active Application Discontinuation
- 2010-11-22 IN IN3130DEN2012 patent/IN2012DN03130A/en unknown
- 2010-11-22 CN CN201080052400.7A patent/CN102753159B/zh active Active
- 2010-11-22 EP EP10778677.4A patent/EP2503999B1/en active Active
- 2010-11-22 ES ES10778677.4T patent/ES2450423T3/es active Active
- 2010-11-22 JP JP2012539355A patent/JP5707009B2/ja active Active
- 2010-11-22 BR BR112012012108A patent/BR112012012108A2/pt not_active Application Discontinuation
- 2010-11-22 WO PCT/EP2010/067938 patent/WO2011061332A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010320823B2 (en) | 2014-06-26 |
| EP2332525A1 (en) | 2011-06-15 |
| EP2503999B1 (en) | 2013-12-25 |
| US20120238639A1 (en) | 2012-09-20 |
| CA2776855C (en) | 2017-10-24 |
| WO2011061332A1 (en) | 2011-05-26 |
| AU2010320823A1 (en) | 2012-07-12 |
| BR112012012108A2 (pt) | 2016-04-05 |
| EP2503999A1 (en) | 2012-10-03 |
| KR20120104262A (ko) | 2012-09-20 |
| ES2450423T3 (es) | 2014-03-24 |
| JP5707009B2 (ja) | 2015-04-22 |
| CN102753159B (zh) | 2014-03-12 |
| CA2776855A1 (en) | 2011-05-26 |
| MX2012005881A (es) | 2012-06-19 |
| CN102753159A (zh) | 2012-10-24 |
| JP2013511496A (ja) | 2013-04-04 |
| US8796340B2 (en) | 2014-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2013001677A (es) | Formulaciones estables de linaclotida. | |
| BR112014009087A2 (pt) | formulações de etanercept estabilizadas com xilitol | |
| WO2011041729A3 (en) | Compounds as lysophosphatidic acid receptor antagonists | |
| WO2011017350A3 (en) | Compounds as lysophosphatidic acid receptor antagonists | |
| WO2011041461A3 (en) | Polycyclic compounds as lysophosphatidic acid receptor antagonists | |
| EA201290982A1 (ru) | Фармацевтические композиции, препятствующие злоупотреблению | |
| BR112012012081A2 (pt) | método para o processamento de um arquivo de imagens médicas kobitidas em um procedimento de imagem guiada por protocolo ,equipamento para o processamento de um arquivo de imagens médicas obtidas por um procedimento de imagem guiada por protocolo e elemamto de programa de computador contendo conjuntos de instruções | |
| ZA200809864B (en) | Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic | |
| MX2011011428A (es) | Derivados de acido sulfamoilbenzoico como antagonistas de trpm8. | |
| EA201590805A1 (ru) | Композиция с немедленным и пролонгированным высвобождением | |
| WO2011017502A3 (en) | Linaclotide-containing formulations for oral administration | |
| WO2010021607A3 (en) | Pharmaceutical formulation | |
| WO2011157722A3 (en) | Solid ivabradine-containing composition | |
| MY168212A (en) | A new therapeutical composition containing apomorphine as active ingredient | |
| MX340147B (es) | Composiciones farmacéuticas y nutracéuticas del ácido abscísico. | |
| WO2013134534A3 (en) | Solid state forms of cabazitaxel and processes for preparation thereof | |
| WO2011069037A3 (en) | Stabilization and storage of biological pharmaceutical compositions | |
| WO2010049449A3 (en) | Novel salts of sunitinib | |
| UA110979C2 (uk) | Рідка фармацевтична композиція, яка включає нітизинон | |
| WO2013114400A3 (en) | Compressed pharmaceutical compositions of atypical antipsychotics | |
| MX2010004899A (es) | Conjugados de neurturina novedosos para uso farmaceutico. | |
| EA201200485A1 (ru) | Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол | |
| WO2009140105A3 (en) | Formulations for cathepsin k inhibitors | |
| WO2013074871A3 (en) | Humanin analogs | |
| IL206739A (en) | An injectable drug containing silitol as an active substance |